Coronavirus: No significant benefit of Umifenovir in COVID-19 treatment, says Glenmark

By: |
October 9, 2020 8:01 PM

As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir.

"These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection," Monika Tandon Senior VP & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals said.

Drug firm Glenmark Pharmaceuticals on Friday said the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients.

The clinical study evaluated the possible superiority of the combination’s efficacy against Favipiravir monotherapy, Glenmark said in a statement.

As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added.

This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said.

“These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection,” Monika Tandon Senior VP & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19 vaccine: Serum Institute SEZ seeks customs duty waiver for local supplies
2Covid-19: No paucity, India in ‘extremely comfortable position’ in oxygen supply, says Health Ministry
3COVID-19: ICMR official warns against reinfection after recovery